New research about short-term, limited-duration health plans shows that none of the plans studied covered pre-existing conditions and all had coverage limits, according to a new report from Milliman, an actuarial consulting firm. Only one-third of the plans covered prescription drugs and only 42% covered mental health, according to the report.
For an article on short-term health plans, journalist Nancy Metcalf found an ideal source: Stewart Lamotte, a 64-year-old retired restaurateur from Lawrenceville, Ga.
In a story that Consumer Reports published in December 2017, “Is Short-Term Health Insurance a Good Deal?”, Metcalf explained that when LaMotte shopped for health insurance, he didn’t qualify for a tax credit under the Affordable Care Act. Also, he balked at the $1,000 monthly premium and a deductible of $6,500 that was required for an ACA-compliant health insurance policy. Continue reading
President Donald Trump’s decision to declare opioid addiction a national emergency could be at least a step toward addressing the complex crisis blamed for claiming more than 33,000 lives in 2015.
The emergency declaration potentially could be used to expedite state responses, dispatch U.S. Public Health Service personnel to hard-hit communities and step up requirements for prescriber education, according to Andrew Kolodny, co-director of opioid policy research at Brandeis University’s Heller School for Social Policy and Management, who was interviewed for a Washington Post story. Continue reading
State-run electronic databases that collect opioid prescription information are being hailed as an effective tool to curb opioid abuse in a new report released last week by the Centers for Disease Control and Prevention (CDC).
The CDC report got a lot of press, mainly for its primary findings that opioid prescriptions have dropped in recent years but still remained three times higher in 2015 than in 1999. The peak opioid prescribing year was 2010, according to the CDC. Continue reading
Many Americans think they pay too much for their prescription drugs, especially those who need life-saving medications for cancer and hepatitis C. Why are drug costs so high in the United States? How can reporters better explain the cost squeeze to their audiences?
These were among the questions that Sarah Emond, M.P.P., executive vice president at the Institute for Clinical and Economic Review (ICER) in Boston and Peter Bach, M.D., director of the Memorial Sloan Kettering’s Center for Health Policy and Outcomes in New York City addressed at the Feb. 15 meeting of AHCJ’s New York chapter. Dan Goldberg of Politico moderated the session. Continue reading